Subjects Through the Application of the Mindera Kit Part 2

Launched by MINDERA HEALTH · May 21, 2021

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Subject must have the ability to understand and sign written informed consent.
• • 2. Subject must be an adult male or female adult who is ≥ 18 years of age at the time of screening.
• • 3. Subject must be diagnosed with psoriasis by either a dermatologist or a rheumatologist, with the affected area of ≥ 2 centimeters in diameter.
• • 4. Subjects must be treated with anti-TNF-α (or biosimilar) therapy once enrolled in the study.A two-week period is required to washout of the previous biologic when switching therapies.
• • Exclusion Criteria
• • 1. Subject is unable or unwilling to give written informed consent and/or to comply with study procedures.
• • 2. Subject has had usage of topical psoriasis treatments on study lesion within 2 weeks prior to baseline studyvisit and unwilling to washout.
• • 3. Subjects currently treated with Hydroxychloroquine (Plaquenil), unless otherwise approved by Sponsor